Recursion Pharmaceuticals Inc [RXRX] stock is trading at $5.50, up 3.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RXRX shares have gain 21.95% over the last week, with a monthly amount drifted -16.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock has seen the most recent analyst activity on May 22, 2023, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $8. Previously, Needham started tracking the stock with Buy rating on March 16, 2023, and set its price target to $17. On September 16, 2022, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $20 on the stock. BofA Securities downgraded its rating to a Neutral but stick to its price target of $10 on April 18, 2022. SVB Leerink downgraded its rating to a Mkt Perform but $10 remained the price target by the analyst firm on March 04, 2022. Berenberg started tracking with a Buy rating for this stock on September 21, 2021, and assigned it a price target of $37. In a note dated May 11, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $33 on this stock.
Recursion Pharmaceuticals Inc [RXRX] stock has fluctuated between $3.79 and $12.36 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $5.50 at the most recent close of the market. An investor can expect a potential return of 9.09% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
Recursion Pharmaceuticals Inc [NASDAQ:RXRX] reported sales of 58.84M for the trailing twelve months, which represents a drop of -58.26%. Gross Profit Margin for this corporation currently stands at 0.11% with Operating Profit Margin at -8.15%, Pretax Profit Margin comes in at -7.9%, and Net Profit Margin reading is -7.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.73 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.31 points at the first support level, and at 5.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.61, and for the 2nd resistance point, it is at 5.72.
Ratios To Look Out For
For context, Recursion Pharmaceuticals Inc’s Current Ratio is 3.81. Also, the Quick Ratio is 3.81, while the Cash Ratio stands at 3.17. Considering the valuation of this stock, the price to sales ratio is 37.58, the price to book ratio is 2.11.
Transactions by insiders
Recent insider trading involved Gibson Christopher, Chief Executive Officer, that happened on Mar 27 ’25 when 0.14 million shares were sold. Officer, Gibson Christopher completed a deal on Mar 27 ’25 to buy 0.14 million shares. Meanwhile, Chief Executive Officer Gibson Christopher sold 20000.0 shares on Mar 05 ’25.
